Extract
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic lung disorder caused by immunological reactions targeted against Aspergillus fumigatus colonising the airways of asthma and cystic fibrosis patients [1]. If undiagnosed or inappropriately treated, the inflammatory process can progress perpetually, culminating in end-stage respiratory disease. Oral glucocorticoids are the treatment of choice in ABPA; antifungal triazoles are good alternatives [2]. Treatment response in ABPA is assessed using a composite of clinical symptoms, serum total IgE, chest radiograph and spirometry [3]. Notably, the minimal important difference (MID) for forced expiratory volume in the first second (FEV1) in ABPA remains unknown. The MID is the smallest change that the patients perceive as beneficial. In the current study, we aimed to estimate the MID for FEV1 in patients with ABPA complicating asthma.
Abstract
This study found a minimal important difference of 158 mL (or 17%) for the FEV1 in patients with acute-stage allergic bronchopulmonary aspergillosis complicating asthma treated with prednisolone https://bit.ly/3JvfBmI
Footnotes
Conflict of interest: R. Agarwal has received grant support from Cipla, India, on research in ABPA. The remaining authors report no potential conflicts of interest.
- Received June 17, 2022.
- Accepted July 26, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
